

## Special Issue

# Chemoprevention Advances in Cancer

### Message from the Guest Editor

Over the past few decades, a tremendous amount of research effort has been directed towards identifying non-toxic chemoprevention or intervention strategies that have the potential to prevent cancer initiation and/or prevent the growth and progression of benign/pre-cancerous lesions to more advanced forms of malignancy. The strategies have focused on discovering novel-dietary and non-dietary agents, lifestyle changes, gut microbiome modulation, and precision nutrition-based intervention strategies. Accordingly, in this Special Issue focused on Chemoprevention Advances in Cancer, we welcome original research articles or comprehensive review articles focused on the efficacy and/or the delineation of action mechanisms relating to non-toxic natural/synthetic agents or intervention strategies that show protective efficacy against the growth and progression of cancers.

---

### Guest Editor

Dr. Komal Raina

1. Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA
2. Department of Pharmaceutical Sciences, South Dakota State University, Brookings, SD 57007, USA

---

### Deadline for manuscript submissions

closed (1 December 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/132590](https://mdpi.com/si/132590)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)